EUCTR2020-005833-34-ES进行中（未招募）1 期
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors - RINGSIDE
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 192
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. At least 18 years of age (inclusive) at the time of signing the ICF.
- •2. Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by = 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.
- •3. At least 1 measurable lesion amenable to volume measurements by MRI at screening
- •4. One of the following:
- •Treatment naïve subjects whose disease is not amenable to surgery without the risk of significant morbidity; OR
- •Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy).
- •5. A desmoid tumor in which continued progressive disease will not result in immediate significant risk to the subject.
- •6. Agrees to provide formalin-fixed paraffin embedded (FFPE) archival or fresh tumor tissue.
- •7. Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.
- •8. Male or female subjects.
- •9. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) within 24 hours prior to the start of investigational product (IP). An extension up to 72 hours is permissible in situations where results cannot be obtained within the standard 24 hour window.
- •10. WOCBP and men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of the treatment with IP plus 120 days post-treatment completion. Contraception methods should be consistent with local regulations.
- •11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •1. =12 years of age (inclusive) and = 40 kg at the time of signing the ICF.
- •2. Histologically confirmed desmoid tumor (aggressive fibromatosis) by local pathologist (prior to informed consent) that has progressed by = 20% as measured by RECIST v1.1 within 12 months of the screening visit scan.
- •3. Evidence of measurable disease by CT/MRI scan. Measurable lesions are defined according to RECIST v1.1.
- •4. One of the following:
- •Treatment naïve subjects whose disease is not amenable to surgery without the risk of significant morbidity; OR
- •Recurrent/refractory disease following at least one line of therapy (including surgery, radiation, or systemic therapy).
- •5. A desmoid tumor in which continued progressive disease will not result in immediate significant risk to the subject.
- •6. Agrees to provide FFPE archival or fresh tumor tissue.
- •7. Must be able to swallow whole capsules with no GI condition affecting absorption; nasogastric or G-tube administration is not allowed.
- •Gender and Reproductive Considerations
- •8. Male or female subjects.
- •9. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of hCG) within 24 hours prior to the start of IP. An extension up to 72 hours is permissible in situations where results cannot be obtained within the standard 24-hour window.
- •10. WOCBP and men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of the treatment with IP plus 120 days post-treatment completion. Contraception methods should be consistent with local regulations.
- •11. Subject and/or legally authorized representative (i.e. parent/gua
排除标准
- •1. Diagnosed with a malignancy in the past 2 years. However, subjects with the following diagnoses may enroll as long as there is no current evidence of disease:
- •Non-melanoma skin cancers
- •Melanoma in situ
- •Treated thyroid cancer
- •Treated cervical carcinoma in situ
- •Early-stage prostate cancer that has undergone definitive treatment or under active surveillance
- •2. Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn’s disease
- •3. Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy =7 days prior to administration of IP
- •4. Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina pectoris, or has NYHA Class III or IV heart failure, symptomatic ventricular arrhythmias, sustained ventricular tachycardia, TdP, the long QT syndrome, pacemaker dependence, or electrocardiographic evidence of acute ischemia
- •5. History of additional risk factors for TdP
- •6. Unstable or severe uncontrolled medical condition or any important medical illness or abnormal laboratory finding
- •7. Pregnant or breastfeeding or expecting to conceive children within the projected duration of the study
- •8. ECOG performance status =2
- •9. Abnormal organ and marrow function at Screening defined as:
- •a. Neutrophils <1500/mm3
- •b. Platelet count <100,000/mm3
- •c. Hemoglobin <9 g/dL
- •d. Electrolytes (potassium, calcium, magnesium, and phosphorus, using corrected value if low serum albumin level is present) outside the normal limits of the local laboratory
- •e. Total bilirubin >1.5x ULN (except known Gilbert’s syndrome >3x ULN)
- •f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >2.5x ULN
- •g. Serum creatinine > ULN and creatinine clearance (CrCl) <60 mL/min
- •h. Uncontrolled triglyceride =Grade 2 elevations per CTCAE v5.0 (>300 mg/dL or >3.42 mmol/L)
- •10. ECG Exclusions
- •a. Mean QT interval corrected for heart rate using Fridericia’s formula (QTcF) =450 msec
- •b. QRS duration > 110 ms
- •c. PR interval > 240 ms
- •d. Marked ST-T wave abnormalities which would make it difficult to measure the QT interval
- •11. Any treatments for desmoid tumors within 4 weeks prior to first dose
- •12. Chronic NSAIDs for the treatment of desmoid tumors within 4 weeks of first dose
- •13. Prior treatment with GSI or other agents targeting the Notch pathway
- •14. Use of strong inhibitors of CYP3A4 or strong inducers of CYP3A4
- •18. Contraindication to MRI
- •1. Diagnosed with a malignancy in the past 2 years. However, subjects with the following diagnoses may enroll as long as there is no current evidence of disease:
- •Non-melanoma skin cancers
- •Melanoma in situ
- •Treated thyroid cancer
- •Treated cervical carcinoma in situ
- •Early-stage prostate cancer that has undergone definitive treatment or under active surveillance
- •2. Current or recent (within 2 months of IP administration) GI disease or disorders that increase the risk of diarrhea, such as inflammatory bowel disease and Crohn’s disease
- •3. Evidence of uncontrolled, active infection, requiring systemic anti-bacterial, anti-viral or anti-fungal therapy =7 days prior to administration of IP
- •4. Myocardial infarction within 6 months prior to enrollment, greater than Class 1 angina pectoris, or has NYHA Class III or IV heart failure, symptomatic ventricular arrhythmias, sustained ventricular tachycardia, TdP, the long QT syndrome, pacemaker dependence
研究者
相似试验
招募中
1 期
A study of AL102 in Progressing Desmoid TumorsEUCTR2020-005833-34-PLAyala Pharmaceuticals, Inc.192
进行中（未招募）
1 期
A study of AL102 in Progressing Desmoid TumorsProgressing desmoid tumorsMedDRA version: 20.1Level: PTClassification code 10059352Term: Desmoid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005833-34-FRAyala Pharmaceuticals, Inc.192
招募中
1 期
A study of AL102 in Progressing Desmoid TumorsProgressing desmoid tumorsMedDRA version: 20.1Level: PTClassification code 10059352Term: Desmoid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005833-34-DEImmunome, Inc.192
进行中（未招募）
1 期
A study of AL102 in Progressing Desmoid TumorsEUCTR2020-005833-34-NLAyala Pharmaceuticals, Inc.192
招募中
3 期
RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid TumorsDesmoid tumorsdesmoiddesmoid tumorsNL-OMON56437Immunome, Inc10